Qiagen Management

Management Kriterienprüfungen 4/4

Qiagen's CEO ist Thierry Bernard , ernannt in Oct 2019, hat eine Amtszeit von 4.67 Jahren. Die jährliche Gesamtvergütung beträgt $1.99M , bestehend aus 49.1% Gehalt und 50.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.11% der Aktien des Unternehmens, im Wert von €9.55M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.4 Jahre bzw. 9.2 Jahre.

Wichtige Informationen

Thierry Bernard

Geschäftsführender

US$2.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	49.1%
Amtszeit als Geschäftsführer	4.9yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	6.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Thierry Bernard im Vergleich zu den Einnahmen von Qiagen verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	US$73m
Mar 31 2024	n/a	n/a	US$337m
Dec 31 2023	US$2m	US$979k	US$341m
Sep 30 2023	n/a	n/a	US$485m
Jun 30 2023	n/a	n/a	US$337m
Mar 31 2023	n/a	n/a	US$353m
Dec 31 2022	US$10m	US$950k	US$423m
Sep 30 2022	n/a	n/a	US$488m
Jun 30 2022	n/a	n/a	US$539m
Mar 31 2022	n/a	n/a	US$563m
Dec 31 2021	US$2m	US$900k	US$513m
Sep 30 2021	n/a	n/a	US$311m
Jun 30 2021	n/a	n/a	US$480m
Mar 31 2021	n/a	n/a	US$449m
Dec 31 2020	US$2m	US$900k	US$359m
Sep 30 2020	n/a	n/a	US$191m
Jun 30 2020	n/a	n/a	US$14m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$650k	-US$41m

Vergütung im Vergleich zum Markt: ThierryDie Gesamtvergütung ($USD1.99M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.82M).

Entschädigung vs. Einkommen: ThierryDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Thierry Bernard (60 yo)

4.9yrs

Amtszeit

US$1,991,874

Vergütung

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board since 2021 and had been its Interim Chief Executive Officer since Octo...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thierry Bernard	CEO, MD & Member of Management Board	4.9yrs	US$1.99m	0.14% $ 12.9m
Roland Sackers	CFO, MD & Member of Management Board	20.7yrs	US$1.07m	0.19% $ 16.9m
Antonio Santos	Senior VP & Head of Global Operations	2.4yrs	keine Daten	keine Daten
John Gilardi	Vice President of Corporate Communications & Investor Relations	13.9yrs	keine Daten	keine Daten
Stephany Foster	Senior VP & Head of Human Resources	4.9yrs	keine Daten	keine Daten
Thomas Schweins	Senior Vice President of Life Science Business Area	6.7yrs	keine Daten	keine Daten
Thomas Theuringer	Senior Director & Head of External Communications	no data	keine Daten	keine Daten
Jean-Pascal Viola	Senior VP & Head of Corporate Strategy and Business Development	9.3yrs	keine Daten	keine Daten
Jonathan Sheldon	Senior VP & Head of the QIAGEN Digital Insights Business Area	6.7yrs	keine Daten	keine Daten
Fernando Beils	Senior VP & Head of the Molecular Diagnostics Business Area	no data	keine Daten	keine Daten
Nitin Sood	Senior VP & Head of the Life Sciences Business Area	no data	keine Daten	keine Daten

6.7yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: 0RLTDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Stephen Rusckowski	Independent Member of Supervisory Board	1.4yrs	US$46.07k	0.000010% $ 896.3
Metin Colpan	Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board	20.7yrs	US$86.50k	0.080% $ 7.1m
Elizabeth Tallett	Independent Member of the Supervisory Board	13.3yrs	US$101.50k	0.022% $ 2.0m
Eva Pisa	Independent Member of the Supervisory Board	2.3yrs	US$68.50k	keine Daten
Lawrence Rosen	Independent Chairman of Supervisory Board	11.3yrs	US$188.50k	0.0067% $ 601.4k
Toralf Haag	Independent Member of the Supervisory Board	3.7yrs	US$82.50k	0.0012% $ 105.8k
Elaine Mardis	Independent Member of the Supervisory Board	10.3yrs	US$79.50k	0.0018% $ 164.9k
Peter Kaspar	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Ross Levine	Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board	8.7yrs	US$68.50k	0.0075% $ 674.9k
Patrice Nordmann	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Neville Sanjana	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Sarah Polonius-Teichmann	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten

9.5yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: 0RLTDie Vorstandsmitglieder gelten als erfahren (9.2 Jahre durchschnittliche Amtszeit).

Qiagen Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

CFO, MD & Member of Management Board recently sold €677k worth of stock

Qiagen N.V., Annual General Meeting, Jun 21, 2024

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Board Member recently sold €204k worth of stock

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold €1.4m worth of stock

Recent updates

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

CFO, MD & Member of Management Board recently sold €677k worth of stock

Qiagen N.V. to Report First Half, 2024 Results on Aug 16, 2024

Qiagen N.V. Updates Earnings Guidance for the Full Year 2024

Qiagen N.V. to Report Q2, 2024 Results on Jul 31, 2024

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care

Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine

QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret

Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results

Qiagen N.V., Annual General Meeting, Jun 21, 2024

QIAGEN Announces the Availability of QCI Secondary Analysis

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.39 in 1Q 2023)

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Full year 2023 earnings released: EPS: US$1.53 (vs US$2.61 in FY 2022)

Full year 2023 earnings released: EPS: US$1.53 (vs US$2.61 in FY 2022)

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 3Q 2022)

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.42 in 2Q 2022)

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Now 21% undervalued

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 84%

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings released: EPS: US$2.53 (vs US$2.36 in FY 2021)

Board Member recently sold €204k worth of stock

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division

Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million.

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million.

QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer

Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance

Third quarter 2022 earnings released: EPS: US$0.36 (vs US$0.58 in 3Q 2021)

Qiagen N.V. Revises Earnings Guidance for the Year 2022

Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022

Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses

QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Now 20% undervalued

Second quarter 2022 earnings released: EPS: US$0.42 (vs US$0.53 in 2Q 2021)

QIAGEN Adds New Biopharma Products to QIAcuity Digital PCR Portfolio and Launches Expert Custom Assay Design Service

Qiagen N.V. Raises Earnings Guidance for the Full Year 2022

Qiagen N.V. to Report Q2, 2022 Results on Jul 27, 2022

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold €1.4m worth of stock

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Qiagen N.V., Annual General Meeting, Jun 23, 2022

First quarter 2022 earnings released: EPS: US$0.68 (vs US$0.57 in 1Q 2021)